[HTML][HTML] 2, 5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis
B Pan, Z Chen, X Zhang, Z Wang, Y Yao… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background 2, 5-dimethylcelecoxib (DMC), a derivative of celecoxib, is an inhibitor of
microsomal prostaglandin E synthase-1 (mPGES-1). Our previous studies have …
microsomal prostaglandin E synthase-1 (mPGES-1). Our previous studies have …
[HTML][HTML] 2, 5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
Z Chen, Y Chen, L Peng, X Wang… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background 2, 5-dimethylcelecoxib (DMC) is a targeted inhibitor of microsomal
prostaglandin E synthase-1 (mPGES-1), a key enzyme in the PGE2 synthesis pathway of …
prostaglandin E synthase-1 (mPGES-1), a key enzyme in the PGE2 synthesis pathway of …
[HTML][HTML] Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization
X Xun, C Zhang, S Wang, S Hu, X Xiang… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Objective: Due to the tumor immune microenvironment (TIME) complexity and cancer
heterogeneity, the clinical outcomes of hepatocellular carcinoma (HCC) are barely elicited …
heterogeneity, the clinical outcomes of hepatocellular carcinoma (HCC) are barely elicited …
[HTML][HTML] Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN
TH Chu, HH Chan, HM Kuo, LF Liu, TH Hu, CK Sun… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several
types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib …
types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib …
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor
JS Chen, CH Chou, YH Wu, MH Yang, SH Chu… - Scientific reports, 2022 - nature.com
Immune checkpoint inhibitors (ICIs) have shown clinical benefit in solid tumors, with modest
rates of clinical response. Hence, improved therapeutic approaches need to be investigated …
rates of clinical response. Hence, improved therapeutic approaches need to be investigated …
Jianpi Huayu Decoction Attenuates the Immunosuppressive Status of H22 Hepatocellular Carcinoma-Bearing Mice: By Targeting Myeloid-Derived Suppressor Cells
Y Xie, Y Zhang, X Wei, C Zhou, Y Huang… - Frontiers in …, 2020 - frontiersin.org
Tumor-induced immunosuppressive microenvironment in which myeloid-derived suppressor
cells (MDSCs) plays an important role, remains an obstacle for effective oncotherapy …
cells (MDSCs) plays an important role, remains an obstacle for effective oncotherapy …
Gehua Jiecheng decoction inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice by improving tumor immunosuppression microenvironment
C Cheng, Q Shou, J Lang, L Jin, X Liu… - Frontiers in …, 2020 - frontiersin.org
Gehua Jiecheng Decoction (GHJCD), a famous traditional Chinese medicine, has been
used in the prevention and treatment of precancerous lesion of liver cancer, but its active …
used in the prevention and treatment of precancerous lesion of liver cancer, but its active …
Enhancing NKT cell-mediated immunity against hepatocellular carcinoma: role of XYXD in promoting primary bile acid synthesis and improving gut microbiota
Z Deng, Z Ouyang, S Mei, X Zhang, Q Li, F Meng… - Journal of …, 2024 - Elsevier
Ethnopharmacological relevance 'Xiayuxue decoction'(XYXD) is a traditional Chinese
medicine compound, composing of three natural medicines: Rheum officinale Baill., Prunus …
medicine compound, composing of three natural medicines: Rheum officinale Baill., Prunus …
Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA‐200/PD‐L1 Pathway
S Guangshun, S Guoqiang, C Xin, K Xiangyi… - Journal of …, 2022 - Wiley Online Library
Background. Hepatocellular carcinoma (HCC) has become the sixth most common cancer
and the third leading cause of cancer death in the world. Although the research …
and the third leading cause of cancer death in the world. Although the research …
Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy
Objective Myeloid-derived suppressor cells (MDSCs) contribute to tumour
immunosuppressive microenvironment and immune-checkpoint blockade resistance …
immunosuppressive microenvironment and immune-checkpoint blockade resistance …